Abstract
Since 2016, the immunotherapeutic agents targeting PD-1 and PD-L1 are an integral part in first-line and second-line treatment of advanced or metastatic urothelial cancer. By PD-1 and PD-L1 inhibition with these drugs, the immune system is supposed to regain the capacity to actively kill cancer cells. Meanwhile, PD-L1 assessment is prescribed for patients not being eligible for platinum-based chemotherapy in first-line settings in metastatic disease (for monotherapy with atezolizumab or pembrolizumab) and for patients who are intended to receive adjuvant nivolumab treatment following radical cystectomy. Several challenges which are highlighted in this chapter affect PD-L1 testing in daily routine including availability of representative tissue materials, inter-observer variability, and different available PD-L1 immunohistochemistry assays with different analytical properties.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Malats N, Real FX (2015) Epidemiology of bladder cancer. Hematol Oncol Clin North Am 29(2):177–189, vii. https://doi.org/10.1016/j.hoc.2014.10.001
Knowles MA, Hurst CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25–41. https://doi.org/10.1038/nrc3817
Powles T, Bellmunt J, Comperat E et al (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 33(3):244–258. https://doi.org/10.1016/j.annonc.2021.11.012
Humphrey PA, Moch H, Cubilla AL et al (2016) The 2016 WHO classification of Tumours of the urinary system and male genital organs-part B: prostate and bladder Tumours. Eur Urol 70(1):106–119. https://doi.org/10.1016/j.eururo.2016.02.028
Witjes JA, Bruins HM, Cathomas R et al (2021) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol 79(1):82–104. https://doi.org/10.1016/j.eururo.2020.03.055
Jang A, Adler DM, Rauterkus GP et al (2021) Immunotherapies in genitourinary oncology: where are we now? Where are we going? Cancers (Basel) 13(20). https://doi.org/10.3390/cancers13205065
Labadie BW, Balar AV, Luke JJ (2021) Immune checkpoint inhibitors for genitourinary cancers: treatment indications, investigational approaches and biomarkers. Cancers (Basel) 13(21). https://doi.org/10.3390/cancers13215415
Lopez-Beltran A, Lopez-Rios F, Montironi R et al (2021) Immune checkpoint inhibitors in urothelial carcinoma: recommendations for practical approaches to PD-L1 and other potential predictive biomarker testing. Cancers (Basel) 13(6). https://doi.org/10.3390/cancers13061424
Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67–76. https://doi.org/10.1016/S0140-6736(16)32455-2
Bellmunt J, Bajorin DF (2017) Pembrolizumab for advanced urothelial carcinoma. N Engl J Med 376(23):2304. https://doi.org/10.1056/NEJMc1704612
Baldini C, Champiat S, Vuagnat P et al (2019) Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential. Onco Targets Ther 12:2505–2512. https://doi.org/10.2147/OTT.S141040
Sharma P, Retz M, Siefker-Radtke A et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312–322. https://doi.org/10.1016/S1470-2045(17)30065-7
Powles T, Park SH, Voog E et al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 383(13):1218–1230. https://doi.org/10.1056/NEJMoa2002788
Eckstein M, Cimadamore A, Hartmann A et al (2019) PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med 7(22):690. https://doi.org/10.21037/atm.2019.10.24
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma, assessed 1/13/23
Eckstein M, Erben P, Kriegmair MC et al (2019) Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer 106:234–243. https://doi.org/10.1016/j.ejca.2018.11.007
Gevaert T, Cimadamore A, Montironi R et al (2021) PD-L1 testing for urothelial carcinoma: interchangeability, reliability and future perspectives. Curr Drug Targets 22(2):162–170. https://doi.org/10.2174/1389450121666200510015216
Erlmeier F, Klumper N, Landgraf L et al (2022) Spatial Immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur Urol 83:133. https://doi.org/10.1016/j.eururo.2022.10.020
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Bahlinger, V., Hartmann, A., Eckstein, M. (2023). Assessment of PD-L1 Status in Urothelial Cancer. In: Hoffmann, M.J., Gaisa, N.T., Nawroth, R., Ecke, T.H. (eds) Urothelial Carcinoma. Methods in Molecular Biology, vol 2684. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3291-8_15
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3291-8_15
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3290-1
Online ISBN: 978-1-0716-3291-8
eBook Packages: Springer Protocols